Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and ...

The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.

CosmoSort enhances flexibility and reduces the cost and data load of whole-slide sequencing—paving the way for functional profiling of spatially distinct microenvironments. Since its founding in 2022, ...

The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.

Evaxion Biotech (EVAX) shares fell over 25% premarket on Thursday after the company priced an offering to raise $10.8M. The sale comprises 3,997,361 of the company's American Depositary Shares and ...

Investing in biotech can be highly rewarding but is fraught ... As we can see above (slide taken from a recent presentation) Septerna continues to work on several assets, including its next ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

Several biotech firms have gone public this year ... Revenue rose year over year, and the stock reversed its recent slide afterward. It is still down about 12% year to date, but the $21.35 ...